Aquestive Therapeutics (AQST) Gross Profit (2017 - 2026)

Aquestive Therapeutics' Gross Profit history runs 10 years deep, the most recent figure standing at $11.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 116.59% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at -$17.0 million (down 142.21% YoY), while the FY2025 annual figure was -$17.6 million, down 144.39% from the prior year.
• Gross Profit was $11.0 million for Q1 2026 at Aquestive Therapeutics, up from -$44.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $24.8 million in Q4 2022 to a low of -$44.8 million in Q4 2025.
• Historically, Gross Profit has averaged $6.6 million across 5 years, with a median of $8.1 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Gross Profit soared 221.1% in 2022, then tumbled 710.36% in 2025.
• A 5-year view of Gross Profit shows it stood at $24.8 million in 2022, then sank by 68.81% to $7.7 million in 2023, then dropped by 4.88% to $7.3 million in 2024, then sank by 710.36% to -$44.8 million in 2025, then jumped by 124.48% to $11.0 million in 2026.
• The last three Gross Profit figures came in at $11.0 million (Q1 2026), -$44.8 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.